Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis

  • End date
    Dec 29, 2021
  • participants needed
  • sponsor
    Eli Lilly and Company
Updated on 12 September 2021
body mass index
chronic pain
knee pain


This study is being done to test the safety and efficacy of LY3556050 for the treatment of osteoarthritis pain. This trial is part of the chronic pain master protocol (H0P-MC-CPMP) which is a protocol to accelerate the development of new treatments for chronic pain.

Condition Arthritis, Osteoarthritis, Arthritis and Arthritic Pain, Arthritis and Arthritic Pain (Pediatric), degenerative arthritis
Treatment Placebo, LY3556050
Clinical Study IdentifierNCT04627038
SponsorEli Lilly and Company
Last Modified on12 September 2021


Yes No Not Sure

Inclusion Criteria

Have a visual analog scale (VAS) pain value 40 and <95 during screening
Have a history of daily pain for at least 12 weeks based on participant report or medical history
Have a body mass index <40 kilograms per meter squared (kg/m) (inclusive)
Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation
Are willing to discontinue all medications taken for chronic pain conditions for the duration of the study
Have presence of index knee pain for >12 weeks at screening
Have an x-ray supporting diagnosis of osteoarthritis according to the American College of Rheumatology with a Kellgren-Lawrence grade 2 to 4 radiographic classification of index knee
Are men, or women able to abide by reproductive and contraceptive requirements

Exclusion Criteria

Have second- or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia
Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques)
Have surgery planned during the study for any reason, related or not to the disease state under evaluation
Have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation
Have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision
Have a substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)
Have a positive human immunodeficiency virus (HIV) test result at screening
Are in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide
Have an intolerance to acetaminophen or paracetamol or any of its excipients
Have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening
Are largely or wholly incapacitated and unable to participate fully in all protocol procedures, for example, bedridden or confined to a wheelchair, permitting little or no selfcare
Have presence of surgical hardware or other foreign body in the index knee
Have an unstable index joint (such as a torn anterior cruciate ligament)
Have had a surgical procedure or therapeutic injection in the affected knee within 3 months prior to starting the washout period
Have fibromyalgia, chronic pain syndrome, or other concurrent medical or arthritic conditions that could interfere with the evaluation of the index knee
Have a history of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis, or amyloidosis
Have clinical signs and symptoms of active knee infection or crystal disease of the index knee
Have a history of infection in the index joint
Have a history of arthritis due to crystals (e.g., gout, pseudogout)
Have pain or functional impairment due to ipsilateral hip osteoarthritis
Have a history within 2 years prior to screening or current evidence of syncope, presyncope, uncontrolled vertigo, or postural dizziness, judged to be clinically significant by the investigator
Have clinically significant active thyroid disease, including Hashimoto's thyroiditis
Are taking metformin therapy
Are pregnant or breastfeeding
Have had any joint replacement such as knee of the lower extremity, such as hip, knee or ankle, in the past 6 months
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note